Ruffer LLP Sells 43,894 Shares of Exelixis, Inc. $EXEL

Ruffer LLP cut its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 36.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,310 shares of the biotechnology company’s stock after selling 43,894 shares during the period. Ruffer LLP’s holdings in Exelixis were worth $3,363,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Forum Financial Management LP bought a new position in Exelixis during the fourth quarter valued at about $241,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Exelixis in the 4th quarter valued at $11,998,000. NorthCrest Asset Manangement LLC increased its holdings in Exelixis by 14.9% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 13,536 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 1,758 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Exelixis by 4,779.4% during the 1st quarter. GAMMA Investing LLC now owns 201,472 shares of the biotechnology company’s stock worth $7,438,000 after buying an additional 197,343 shares during the last quarter. Finally, Merit Financial Group LLC lifted its stake in Exelixis by 154.8% in the 1st quarter. Merit Financial Group LLC now owns 33,453 shares of the biotechnology company’s stock valued at $1,235,000 after purchasing an additional 20,325 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of analyst reports. Guggenheim reiterated a “buy” rating and issued a $45.00 price target on shares of Exelixis in a research report on Tuesday, July 29th. The Goldman Sachs Group assumed coverage on shares of Exelixis in a research report on Wednesday, September 17th. They set a “buy” rating and a $47.00 price objective on the stock. Royal Bank Of Canada lowered their target price on shares of Exelixis from $50.00 to $45.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 29th. Wall Street Zen lowered shares of Exelixis from a “buy” rating to a “hold” rating in a report on Monday, September 15th. Finally, William Blair restated an “outperform” rating on shares of Exelixis in a report on Tuesday, July 29th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.42.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $38.91 on Thursday. The stock has a market cap of $10.47 billion, a PE ratio of 18.71, a price-to-earnings-growth ratio of 0.82 and a beta of 0.32. Exelixis, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $49.62. The stock has a fifty day moving average of $39.20 and a 200-day moving average of $39.70.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.